SANTHERA N |
Date/Time | / |
Chg. / Chg.(%) | - / |
Bid | - |
Ask | - |
Open | - |
Previous Close | - |
High | - |
Low | - |
Volume [CHF] | - |
Volume [Units] | |
Price fixings | |
ISIN | CH0027148649 |
Security | SANN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 0.8120 | ![]() |
449,073 |
Turquoise | 0.81 | ![]() |
6,532 |
Cboe Europe .. | 0.82 | ![]() |
6,469 |
Cboe Europe .. | 0.86 | ![]() |
1,577 |
Lang & Schwa.. | 0.80 | ![]() |
|
Nasdaq Other.. | 1.2000 | 120 | |
London Domes.. | 0.5349 | 2,000 | |
München | 13.700 | 0 | |
Berlin | 13.720 | 0 | |
Frankfurt | 13.6400 | 0 | |
TradeGate | 13.76 | 0 |
News
- Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
03/29/2022 / 07:00 - GlobeNewswire - Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
03/15/2022 / 07:05 - GlobeNewswire - Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing
03/15/2022 / 07:00 - GlobeNewswire - Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing
03/11/2022 / 07:00 - GlobeNewswire - Santhera Signs Gene Therapy Agreement with SEAL Therapeutics
02/28/2022 / 07:00 - GlobeNewswire